Le Lézard
Classified in: Health
Subject: PER

Robert Cimorelli, RPh., SVP of Regulatory and Strategic Operations, Joins Curexa Pharmacy's Executive Team

503A and 503B Compounding Expertise To Fuel Safety, Compliance, and Expansion

EGG HARBOR TOWNSHIP, N.J., Feb. 22, 2024 /PRNewswire/ -- Curexa Pharmacy (Curexa), a leading national pharmacy based in Egg Harbor Township (EHT), New Jersey, proudly announces Robert Cimorelli, RPh., as the new Senior Vice President of Regulatory and Strategic Operations.

Cimorelli brings extensive expertise in pharmaceutical research, product development, quality assurance, regulatory affairs, strategic planning, and operations. His compounding proficiency spans sterile and non-sterile processes for human and veterinary markets, including nuclear medicine. With valuable experience from a top mail-order pharmacy company, Cimorelli is well-equipped to enhance Curexa's operations.

Curexa, an API-connected 503A compounding pharmacy, partners with direct-to-consumer telemedicine wellness brands to offer customized pharmaceutical products. Cimorelli's background with The Ritedose Corporation, Boothwyn Pharmacy, and Pentec Health uniquely positions him to drive growth in the 503A and 503B compounding markets.

Mark K. Taylor, RPh. MBA, President, and CEO of Curexa, expressed excitement about Cimorelli's addition, stating, "Robert's expertise reinforces our commitment to patient safety and FDA compliance."

John Pouschine, Chairman of the Board and Managing Member of Pouschine Cook Capital, a significant shareholder of Curexa, highlighted Cimorelli's role in elevating operational safety, quality, and compliance standards, as well as his contribution to facility design to improve customer service during Curexa's planned expansion.

Originally from Philadelphia, Cimorelli holds a Bachelor of Science in Pharmacy from the Philadelphia College of Pharmacy and Science. He also completed professional certificates in Executive Leadership Principles and Drug and Medical Device Development from the Massachusetts Institute of Technology (MIT). With pharmacist licensure in fifteen states and membership in the International Society of Pharmaceutical Engineering, Cimorelli is dedicated to advancing healthcare solutions at Curexa.

For more information, visit www.curexa.com.


Founded in 2003, Curexa Pharmacy has become a leading provider of compounding, packaging, labeling, and digital and traditional pharmacy solutions for telemedicine and medical providers, veterinarians, manufacturers, and clinical research organizations across the nation. Curexa's broad range of services includes pre-launch support, customized formulations, API integration, packaging/branding, and pharmacy regulatory compliance. For additional information on the company, please visit curexa.com.

[email protected]
(855) 927-0390 x146


These press releases may also interest you

at 09:41
SPARK Neuro, a leader in brain health diagnostics, announces the appointment of Dr. Richard J. Caselli as its Medical Director. With a 35-year career at the Mayo Clinic, Dr. Caselli brings extensive expertise and leadership in neurology and cognitive...

at 09:30
LiveOnNY, the federally designated organ procurement organization (OPO) for the NY Metro region announce strategic collaboration with the National Association of Health Services Executives New York Regional Chapter (NAHSE NYR) to increase organ, eye...

at 09:30
Originally founded in Texas, leading massage and wellness franchise, Massage Heights, inks a multi-unit agreement to continue expanding in their home state. The two new locations will provide an elevated experience to those in the Dallas-Fort Worth...

at 09:30
Annovianttm, Inc., a pioneering company with a breakthrough TxGuardtm technology platform for soft-tissue healing, currently focused on cardiovascular field, proudly announces receipt of a $2.99 million grant (SBIR Phase 2b) from the National...

at 09:27
Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2024 class of Harrington Scholar-Innovators. The scholar awards will support breakthrough new treatments for heart disease, autoimmune disorders, cancer,...

at 09:27
BioArctic AB (publ) hereby announces that the Nomination Committee for BioArctic AB (publ) presents the following proposals regarding the resolution on the number of board members and the election of board members and Chairperson of the Board at the...

News published on and distributed by: